Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Tralokinumab
DRUG: Placebo
BIOLOGICAL: Tdap vaccine
BIOLOGICAL: Meningococcal vaccine

Sponsor

LEO Pharma